Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.44 |
| ▸ | CYP1A1 | P04798 | 2/20 | 0.38 |
| ▸ | CYP1B1 | Q16678 | 2/20 | 0.38 |
| ▸ | CDC25A | P30304 | 1/20 | 0.36 |
| ▸ | CDC25B | P30305 | 1/20 | 0.36 |
| ▸ | CDC25C | P30307 | 1/20 | 0.36 |
| ▸ | DUSP3 | P51452 | 1/20 | 0.36 |
| ▸ | SREBF2 | Q12772 | 1/20 | 0.36 |
| ▸ | CTSG | P08311 | 1/20 | 0.36 |
| ▸ | KLK7 | P49862 | 1/20 | 0.36 |
| ▸ | KLK14 | Q9P0G3 | 1/20 | 0.36 |
| ▸ | KLK5 | Q9Y337 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8244066 | 0.90 | SMN1; SMN2 (0.54) | KDM4EALDH1A1SMN1; SMN2CYP1A1CYP1B1 | |
| SCHEMBL3427491 | 0.87 | KDM4E (0.45) | KDM4EALDH1A1SMN1; SMN2CYP1A1CYP1B1 | |
| SCHEMBL10271655 | 0.85 | KDM4E (0.41) | KDM4EALDH1A1SMN1; SMN2CYP1A1CYP1B1 | |
| SCHEMBL3478856 | 0.85 | TACR3 (0.40) | KDM4EALDH1A1SMN1; SMN2CYP1A1CYP1B1 | |
| SCHEMBL10220208 | 0.85 | KDM4E (0.44) | KDM4EALDH1A1SMN1; SMN2CYP1A1CYP1B1 | |
| SCHEMBL12362342 | 0.83 | KDM4E (0.41) | KDM4EALDH1A1SMN1; SMN2CYP1A1CYP1B1 | |
| SCHEMBL15216084 | 0.82 | ACHE (0.40) | KDM4EALDH1A1SMN1; SMN2CYP1A1CYP1B1 | |
| SCHEMBL313100 | 0.82 | CYP19A1 (0.40) | KDM4EALDH1A1SMN1; SMN2CYP1A1CYP1B1 | |
| SCHEMBL995659 | 0.82 | CYP1A2 (0.39) | KDM4EALDH1A1SMN1; SMN2CYP1A1CYP1B1 | |
| SCHEMBL3429850 | 0.80 | SMN1; SMN2 (0.38) | KDM4EALDH1A1SMN1; SMN2CYP1A1CYP1B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130053577-A1 | ANTIVIRAL COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2013-02-28 | — | — | US | disclosed |
| US-8283442-B2 | Antiviral compounds | GILEAD SCIENCES, INC. (US) | 2012-10-09 | — | — | US | disclosed |
| US-8178491-B2 | Antiviral compounds | GILEAD SCIENCES, INC. (US) | 2012-05-15 | — | — | US | disclosed |
| US-20090257978-A1 | Antiviral coumpounds | GILEAD SCIENCES, INC. (US) | 2009-10-15 | — | — | US | disclosed |
| US-20090186869-A1 | Antiviral compounds | GILEAD SCIENCES, INC. (US) | 2009-07-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090257978-A1 | Antiviral coumpounds | MAVS, ZC3HAV1, EIF2AK2 | KDM4E 2399/4885ALDH1A1 2504/4885SMN1; SMN2 3291/4885 |
| US-20130053577-A1 | ANTIVIRAL COMPOUNDS | MAVS, EIF2AK2, ZC3HAV1 | KDM4E 2496/4885ALDH1A1 3957/4885SMN1; SMN2 1564/4885 |
| US-20090186869-A1 | Antiviral compounds | MAVS, EIF2AK2, ZC3HAV1 | KDM4E 2496/4885ALDH1A1 3957/4885SMN1; SMN2 1564/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.